MXPA04004308A - Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda). - Google Patents

Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda).

Info

Publication number
MXPA04004308A
MXPA04004308A MXPA04004308A MXPA04004308A MXPA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A MX PA04004308 A MXPA04004308 A MX PA04004308A
Authority
MX
Mexico
Prior art keywords
hydrogen
lower alkyl
nmda receptor
receptor ligands
pyridine derivatives
Prior art date
Application number
MXPA04004308A
Other languages
English (en)
Spanish (es)
Inventor
Wyler Rene
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04004308A publication Critical patent/MXPA04004308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA04004308A 2001-11-09 2002-11-02 Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda). MXPA04004308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
PCT/EP2002/012240 WO2003040128A1 (en) 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands

Publications (1)

Publication Number Publication Date
MXPA04004308A true MXPA04004308A (es) 2004-08-11

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004308A MXPA04004308A (es) 2001-11-09 2002-11-02 Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda).

Country Status (16)

Country Link
US (1) US6831087B2 (enExample)
EP (1) EP1448547B1 (enExample)
JP (1) JP4188837B2 (enExample)
KR (1) KR100589995B1 (enExample)
CN (1) CN100516061C (enExample)
AR (1) AR037221A1 (enExample)
AT (1) ATE293619T1 (enExample)
AU (1) AU2002351816B8 (enExample)
BR (1) BR0213977A (enExample)
CA (1) CA2467973C (enExample)
DE (1) DE60203820T2 (enExample)
ES (1) ES2240829T3 (enExample)
MX (1) MXPA04004308A (enExample)
PL (1) PL369544A1 (enExample)
RU (1) RU2303037C2 (enExample)
WO (1) WO2003040128A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
RU2320654C1 (ru) * 2006-05-24 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EP2225237A2 (de) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
EP2225223B1 (de) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)
CN122422302A (zh) * 2023-12-14 2026-07-17 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ATE524440T1 (de) * 1998-05-25 2011-09-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und anwendung
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
DE60203820D1 (de) 2005-05-25
KR20050042252A (ko) 2005-05-06
EP1448547B1 (en) 2005-04-20
KR100589995B1 (ko) 2006-06-19
CA2467973A1 (en) 2003-05-15
JP4188837B2 (ja) 2008-12-03
AU2002351816B8 (en) 2008-04-03
PL369544A1 (en) 2005-05-02
RU2004117595A (ru) 2006-01-10
AR037221A1 (es) 2004-10-27
CA2467973C (en) 2009-09-01
WO2003040128A1 (en) 2003-05-15
JP2005513004A (ja) 2005-05-12
BR0213977A (pt) 2004-08-31
US6831087B2 (en) 2004-12-14
EP1448547A1 (en) 2004-08-25
CN1585762A (zh) 2005-02-23
US20030119870A1 (en) 2003-06-26
AU2002351816B2 (en) 2008-03-06
CN100516061C (zh) 2009-07-22
DE60203820T2 (de) 2006-02-23
ES2240829T3 (es) 2005-10-16
ATE293619T1 (de) 2005-05-15
RU2303037C2 (ru) 2007-07-20

Similar Documents

Publication Publication Date Title
CA2467973A1 (en) Pyridine derivatives as nmda receptor ligands
SE0104332D0 (sv) Therapeutic agents
WO2002022602A3 (en) Triazole compounds useful as protein kinase inhibitors
DE69823648D1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
EP1423370A4 (en) COMPOUNDS BINDING TO THE NUCLEAR FXR-NR1H4 RECEPTOR
AU6272301A (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
DE69120100D1 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
JO2321B1 (en) 4-phenyl-pyridine derivatives
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
GEP20094826B (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
ZA982137B (en) Cycloalkylalkanecarboxamides and their preparation and use.
MY138826A (en) 2,7-substituted indoles
PL339143A1 (en) Tetrahydro-gamma-carbolynes
NZ334736A (en) Acylaminoalkenylene-amide derivatives useful in treatments of the respiratory diseases where it is more specific for NK1 than NK2
BG104983A (en) Aryl fused azapolycyclic compounds
CA2375671A1 (en) 4-phenyl-pyrimidine derivatives
MXPA04003935A (es) Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato.
MXPA04005077A (es) Derivados de benzotiazol.
PL1636217T3 (pl) 1-Imidazobenzotiazole jako ligandy receptora adenozynowego
IL135634A0 (en) 5-htif agonists

Legal Events

Date Code Title Description
FG Grant or registration